Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
- Status
- COMPLETED
- Phase
- PHASE3
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
- Status
- COMPLETED
- Phase
- PHASE3
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- NA
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1